ABBVAbbVie
Is it growing?
Growing: revenue growing +10% year on year, earnings up +69% year on year, and operating margin widening (+6.9 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 26.0% now against 19.1% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is ABBV growing?
AbbVie has grown revenue 4.8% a year over three years and 3.7% a year over five, with earnings per share compounding at −10%.
Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · growing slowly · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +3.7%
Revenue growth, 5-year rate · +4.8% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- −10%
Earnings per share, 3-year rate · revenue +4.8% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 15
Years of annual history on file · FY2011 to FY2025, as filed
Details›
- Revenue FY2021
- $56.2B
- Revenue FY2022
- $58.1B
- Revenue FY2023
- $54.3B
- Revenue FY2024
- $56.3B
- Revenue FY2025
- $61.2B
Annual income statements as filed with the SEC.
Drug Manufacturers, General
The closest names by size in the same industry